Weight loss drug gets US nod to treat sleep apnea; India launch likely next year

Weight loss drug gets US nod to treat sleep apnea; India launch likely next year

IndiaTimes

Published

The US FDA has approved the anti-diabetic drug Zepbound (Tirzepatide) for managing obstructive sleep apnea (OSA) in obese adults. Eli Lilly plans to launch the drug in India by 2025, pending approvals. The treatment is expected to be a breakthrough by aiding weight reduction, which in turn improves breathing during sleep.

Full Article